KRAS and cholangiocarcinoma: Furthermore, molecular concordances between KRAS wildtype mPDAC and cholangiocarcinoma provide impetus toward the future adoption of cholangiocarcinoma-specific treatment strategies in the clinical management of KRAS wildtype mPDAC.